Compare abrdn Income Credit Strategies Fund (ACP) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Charles River Laboratories Intl. Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Charles River Laboratories Intl. Inc trades at $222.49 (market cap $11.01B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 16.8× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| ACP | CRL | |
|---|---|---|
Market Cap | $656.21M | $11.01B |
Sector | Financials | Health |
52-Week High | $5.98 | $231.43 |
52-Week Low | $5.01 | $145.57 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $13.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
CRL trades at $228.68, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported negative net income of -$144.34M in 2025 despite revenue stability around $4.02B, resulting in a high P/E of 684.85. Recent earnings beats and strategic collaborations, such as with Lilly TuneLab (Business Wire, 2026-06-18), highlight operational strengths amid profitability challenges.
Outlook is mixed: strong analyst support (72% buy ratings) and positive cash flow trends contrast with negative margins and high debt. Key risks include sustained unprofitability and competitive pressures, but institutional confidence and technical momentum suggest potential for recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
